Emergent BioSolutions (EBS) Commences Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection
Tweet Send to a Friend
Emergent BioSolutions Inc. (NYSE: EBS) today announced the initiation of a Phase 2 dose ranging study to evaluate the safety ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
